APHINITY: adjuvant pertuzumab added to trastuzumab and chemotherapy in early HER2-positive breast cancer
Adding a second HER2 antibody, pertuzumab, to a year of trastuzumab after surgery reduced recurrences modestly in early HER2-positive breast cancer, with the gain concentrated in women with lymph node involvement.
Overview
Phase 3 placebo-controlled trial of 4,805 patients with operable HER2-positive breast cancer randomised to chemotherapy plus trastuzumab with pertuzumab or placebo for one year.
Three-year invasive disease-free survival was 94.1 percent with pertuzumab against 93.2 percent with placebo (hazard ratio 0.81); in node-positive disease the absolute gain grew to 4.5 percent at six years, with no benefit seen in node-negative disease. Diarrhoea was the main added toxicity.
- Three-year invasive disease-free survival 94.1 percent vs 93.2 percent; hazard ratio 0.81.
- Node-positive subgroup: six-year invasive disease-free survival 87.9 percent vs 83.4 percent.
Dual HER2 blockade after surgery is reserved for node-positive or otherwise higher-risk disease, where the benefit is real but small; node-negative patients can be spared the extra drug.
- Absolute benefit is small and no overall survival difference has emerged.
- Trial predates neoadjuvant therapy as the usual route for stage II to III disease.
Similar pages
not linked directly; found by shared links- Key paperAPT: adjuvant paclitaxel and trastuzumab for small, node-negative HER2-positive breast cancer
Shares Early HER2-positive breast cancer, Trastuzumab, New England Journal of Medicine.
- TrialA Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Brea
Shares Early HER2-positive breast cancer, Pertuzumab, Trastuzumab.
- TermTrastuzumab cardiotoxicity
Shares Early HER2-positive breast cancer, Pertuzumab, Trastuzumab.
- TrialClinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer
- TrialA Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Shares Early HER2-positive breast cancer, Pertuzumab, Trastuzumab.
- TermDual HER2 blockade
Shares APHINITY, Pertuzumab, Trastuzumab.
- TrialA Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial
Shares Pertuzumab, Trastuzumab.
- TrialKRISTINE
Shares Early HER2-positive breast cancer, Pertuzumab, Trastuzumab.